Can Veracyte’s Prosigna data change chemotherapy decisions in high-risk breast cancer?
Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics
Veracyte’s ASCO data could sharpen the case for genomic testing in breast and prostate cancer. Read why adoption still faces hard tests.